After 20 years, Compugen finally finds its mojo
CEO Dr. Anat Cohen-Dayag is confident that, after signing a licensing agreement with Bayer of Germany, Compugen has finally emerged from the doldrums.
The shares of Compugen, a genomics-based drug and diagnostic discovery company, soared by more than 40% on the Tel Aviv Stock Exchange on Monday last week. That dramatic recovery, which raised Compugen’s total share value to more than NIS 1 billion, followed the company’s announcement that it had signed a licensing and collaboration agreement...
Like us on Facebook and get articles directly in your news feed